Hydrogen Peroxide
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | ESKATA | — | 2017-12-14 | fda.gov ↗ |
Trials 46 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT05669560 | Jan 2023 → May 2027 | chronic periodontitis, type 2 diabetes mellitus | University of Oklahoma | Withdrawn | No outcome recorded |
| Phase 0 | NCT05024760 | Jul 2022 → Nov 2025 overdue | mucositis, periodontitis, prosthesis-related infectious disease | Madigan Army Medical Center | Recruiting | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT05570422 | Mar 2026 → Jan 2027 expected | cervical cancer | Kortuc, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT06404190 | May → Aug 2023 | periodontitis | Krishnadevaraya College of Dental Sciences & Hospital | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02757651 | Jan 2017 → Nov 2020 | female breast carcinoma | Institute of Cancer Research, United Kingdom | Completed | No outcome recorded |
| Phase 28 trials | ||||||
| Phase 2 | NCT07713329 | Mar → Jun 2026 | pleural empyema, respiratory tract infectious disorder | Delta University for Science and Technology | Completed | No outcome recorded |
| Phase 2 | NCT04929535 | Sep 2022 → Aug 2023 | basal cell carcinoma, skin squamous cell carcinoma | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Unknown | No outcome recorded |
| Phase 2 | NCT04409873 | Mar 2021 → Sep 2022 | COVID-19, disorder of pharynx | University of California, San Francisco | Terminated | No outcome recorded |
| Phase 2 | NCT03946202 | Jun 2020 → Jun 2028 expected | breast cancer | Institute of Cancer Research, United Kingdom | Recruiting | No outcome recorded |
| Phase 2 | NCT03210337 | Aug 2017 → Mar 2018 | common wart | Aclaris Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03278028 | Jul 2017 → Mar 2018 | common wart | Aclaris Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03224598 | Jun 2017 → Jan 2019 | dermatosis papulosa nigra | Aclaris Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02669862 | Dec 2015 → Sep 2016 | common wart | Aclaris Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 310 trials | ||||||
| Phase 3 | NCT07276672 | Nov 2025 | — | Colgate Palmolive | Completed | No outcome recorded |
| Phase 3 | NCT06957249 | Apr → May 2025 | — | Colgate Palmolive | Completed | No outcome recorded |
| Phase 3 | NCT07351370 | Jan → Jul 2022 | periodontal disorder | Dental School | Completed | No outcome recorded |
| Phase 3 | NCT04438434 | Jun → Jul 2020 | impacted teeth, multiple | University of Milan | Unknown | No outcome recorded |
| Phase 3 | NCT03812510 | Feb → Nov 2019 | common wart | Aclaris Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03687372 | Sep 2018 → Jun 2019 | common wart | Aclaris Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03691831 | Sep 2018 → Apr 2019 | common wart | Aclaris Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02667288 | Jan → Oct 2016 | seborrheic keratosis | Aclaris Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02667275 | Jan → Oct 2016 | seborrheic keratosis | Aclaris Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00978861 | Oct 2008 → Jun 2009 | — | JDC Tech | Completed | No outcome recorded |
| Phase 47 trials | ||||||
| Phase 4 | NCT06045429 | May 2024 → Jun 2025 overdue | — | Charles University, Czech Republic | Recruiting | No outcome recorded |
| Phase 4 | NCT04659928 | Jul 2021 → May 2024 | COVID-19 | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 4 | NCT06110494 | Jul 2020 → Mar 2022 | chronic apical periodontitis, dental pulp disorder | University of Pennsylvania | Completed | No outcome recorded |
| Phase 4 | NCT04407910 | Sep 2018 → Mar 2019 | dental fluorosis | Cukurova University | Completed | No outcome recorded |
| Phase 4 | NCT03514797 | Apr → Jun 2018 | tooth disorder | André Luis Faria e Silva | Completed | No outcome recorded |
| Phase 4 | NCT03262701 | Apr 2018 → Feb 2021 | chronic periodontitis | Loma Linda University | Terminated | No outcome recorded |
| Phase 4 | NCT03487588 | Mar → Nov 2018 | seborrheic keratosis | Aclaris Therapeutics, Inc. | Completed | No outcome recorded |
| Phase not applicable16 trials | ||||||
| — | NCT07534865 | May 2026 → Dec 2028 expected | common wart | First Hospital of China Medical University | Recruiting | No outcome recorded |
| — | NCT07565350 | Oct 2025 → Oct 2027 expected | common wart | First Hospital of China Medical University | Recruiting | No outcome recorded |
| — | NCT07031388 | Jul → Sep 2025 | gingival disorder | Ramziyah Hayder Bakr | Completed | No outcome recorded |
| — | NCT07486245 | Mar → Nov 2025 | pulpitis | CMH Multan Institute of Medical Sciences | Completed | No outcome recorded |
| — | NCT07287956 | Feb 2024 → Jul 2025 | periodontal disorder | King Abdullah University Hospital | Completed | No outcome recorded |
| — | NCT06904118 | Jun → Dec 2023 | dentin sensitivity | Pakistan Institute of Medical Sciences | Completed | No outcome recorded |
| — | NCT06030492 | Jan → Sep 2023 | placenta accreta | Cairo University | Unknown | No outcome recorded |
| — | NCT06812065 | Dec 2022 → Dec 2026 expected | common wart | First Hospital of China Medical University | Recruiting | No outcome recorded |
| — | NCT04341688 | Dec 2021 → Jun 2022 | COVID-19 | Aga Khan University | Unknown | No outcome recorded |
| — | NCT04723446 | May → Oct 2021 | COVID-19 | Queen Mary University of London | Completed | No outcome recorded |
| — | NCT04733196 | Oct → Dec 2020 | gingivitis | Plovdiv Medical University | Completed | No outcome recorded |
| — | NCT04707742 | Jun 2020 → Sep 2021 | COVID-19 | FISABIO Foundation | Completed | No outcome recorded |
| — | NCT03194984 | May 2017 → Jan 2018 | — | Federal University of Uberlandia | Completed | No outcome recorded |
| — | NCT02816593 | Aug 2015 → Jul 2017 | — | Federal University of Minas Gerais | Completed | No outcome recorded |
| — | NCT02603354 | Mar → Apr 2015 | tooth disorder | University of Chile | Completed | No outcome recorded |
| — | NCT03217994 | Jan 2015 → Dec 2016 | tooth disorder | University of Chile | Completed | No outcome recorded |
Also used as a comparator or background therapy in 27 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03678012 Comparator | Jun → Aug 2018 | dental caries | University of Pennsylvania | Completed | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT03434782 Background | Apr → Nov 2017 | dentin sensitivity | Federal University of Pará | Completed | No outcome recorded |
| Phase 1 | NCT03044171 Background | Aug 2016 → Jan 2017 | dentin sensitivity | Federal University of Pará | Completed | No outcome recorded |
| Phase 1 | NCT01008111 Comparator | Oct 2009 → Apr 2013 | — | Wake Forest University | Withdrawn | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01986920 Comparator | Oct 2013 → Feb 2014 | seborrheic keratosis | Aclaris Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT04584684 Comparator | Dec 2020 → Oct 2021 | COVID-19 | University of North Carolina, Chapel Hill | Terminated | No outcome recorded |
| Phase 2 | NCT04717063 Comparator | Nov → Dec 2020 | — | Colgate Palmolive | Completed | No outcome recorded |
| Phase 2 | NCT04626778 Comparator | Oct → Dec 2020 | — | Colgate Palmolive | Completed | No outcome recorded |
| Phase 2 | NCT03536637 Background | May → Dec 2018 | acne | Dermata Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT03148691 Comparator | May 2017 → Feb 2018 | seborrheic keratosis | Aclaris Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02260180 Comparator | Oct 2014 → Mar 2015 | seborrheic keratosis | Aclaris Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02160626 Comparator | Jun → Dec 2014 | seborrheic keratosis | Aclaris Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT05198180 Comparator | Feb → Jun 2022 | plantar wart | Sohag University | Unknown | No outcome recorded |
| Phase 3 | NCT02935114 Comparator | May → Jun 2016 | dentin sensitivity | Federal University of Sergipe | Completed | No outcome recorded |
| Phase 3 | NCT02667236 Comparator | Jan → Oct 2016 | seborrheic keratosis | Aclaris Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT04721457 Comparator | Jan → Mar 2021 | COVID-19 | King Abdulaziz University | Completed | No outcome recorded |
| Phase 4 | NCT04603794 Comparator | Oct → Nov 2020 | COVID-19 | Ohio State University | Unknown | No outcome recorded |
| Phase 4 | NCT03163069 Background | Jan → Jul 2017 | tooth disorder | Fujian Medical University | Completed | No outcome recorded |
| Phase 4 | NCT03019224 Background | Jan → Apr 2016 | dentin sensitivity | University of Campinas, Brazil | Completed | No outcome recorded |
| Phase not applicable8 trials | ||||||
| — | NCT06884813 Background | Mar 2025 → May 2026 overdue | — | King Abdullah University Hospital | Recruiting | No outcome recorded |
| — | NCT07675278 Comparator | Feb 2024 → Jan 2025 | tonsillitis | Rawalpindi Medical College | Completed | No outcome recorded |
| — | NCT06949176 Background | Dec 2023 → Dec 2024 overdue | periapical periodontitis | National and Kapodistrian University of Athens | Active not recruiting | No outcome recorded |
| — | NCT05569590 Background | May → Dec 2021 | — | Dow University of Health Sciences | Completed | No outcome recorded |
| — | NCT03656588 Comparator | Apr 2018 → Jan 2019 | bacterial infectious disease | Rothman Institute Orthopaedics | Unknown | No outcome recorded |
| — | NCT03412071 Comparator | Dec 2017 → Dec 2019 | — | University of Toronto | Unknown | No outcome recorded |
| — | NCT02383992 Comparator | Oct 2015 → Oct 2019 | — | Northwestern University | Withdrawn | No outcome recorded |
| — | NCT02067715 Background | Feb 2014 → May 2015 | tooth disorder | Federal University of Sergipe | Completed | No outcome recorded |
Evidence & citations 21 cited values
Every value below carries the sentence it was read from. 75 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hydrogen Peroxide | “A Phase 2 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of the Safety and Effectiveness of A-101(Hydrogen Peroxide) Topical Solution in Subjects With...” NCT03148691 ↗61“An Open-Label Study Assessing Subject Satisfaction With A-101 Hydrogen Peroxide Topical Solution, 40% (w/w) Treatment for Seborrheic Keratoses of the Face, Neck, and Decolletage” NCT03487588 ↗ “Evaluate the safety and efficacy of hydrogen peroxide, A-101 Solution 40% for the treatment of DPN lesions on subjects with a Fitzpatrick Skin Type of 5 or 6.” NCT03224598 ↗ “KRC-01 is a solution that contains hydrogen peroxide 3% with sodium hyaluronate 1%. Hydrogen peroxide is the active ingredient for this radiosensitizer.” NCT05570422 ↗ “Three 15-minute applications of the 35% hydrogen peroxide gel were performed, totaling 45 minutes in each of the 4 sessions, with a 7-day interval.” NCT03044171 ↗ “Three 15-minute applications of the 35% hydrogen peroxide gel were performed, totaling 45 minutes in each of the 3 sessions, with a 7-day interval.” NCT03434782 ↗ “Participants will receive in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) for the maxillary anterior teeth” NCT03163069 ↗ “In one group, the hemiarcade was bleached with 37.5% hydrogen peroxide (Polaoffice + 37.5% SDI Limited, Bayswater, Australia).” NCT03217994 ↗ “Efficacy of a Toothpaste Containing Hydrogen Peroxide as Compared to a Regular Fluoride Toothpaste Without Hydrogen Peroxide” NCT07276672 ↗ “A 40% hydrogen peroxide bleaching agent was applied twice for 15 min for the in-office bleaching treatment.” PMID 34145478 ↗ Jun 2021 “a 6% hydrogen peroxide with nitrogen-doped titanium dioxide light activated bleaching agent” NCT02603354 ↗ “In-office tooth bleaching with 35% hydrogen peroxide in a single application of 45 minutes.” NCT03514797 ↗ “35% hydrogen peroxide based bleaching agent, Whiteness HP Maxx, FGM, Joinville, SC, Brazil.” NCT02067715 ↗ “1% Hydrogen peroxide (HP® by Karachi Chemicals Products Inc./ ActiveOxy® by Boumatic Inc.)” PMID 32928313 ↗ Sep 2020 “3% hydrogen peroxide (Oroxid®) versus standard of care (0.2% chlorhexidine digluconate)” NCT06045429 ↗ “Over the counter: Oral-B Mouth Sore (Oral-B, USA) contains hydrogen peroxide (H2O2)” NCT04409873 ↗ “Hydrogen peroxide 1% (Oximen® 3%) (Reig Jofré, S.A., Spain).” NCT04707742 ↗ “a Colgate toothpaste with 5% Hydrogen Peroxide and Fluoride” NCT06957249 ↗ “commercial mouthwash containing 1.5% hydrogen peroxide” NCT04717063 ↗ “40% (w/w) hydrogen peroxide topical solution (HP40).” PMID 30365590 ↗ Oct 2018 “Peroxyl mouthwash (1.5% hydrogen peroxide)” NCT04626778 ↗ “Hydrogen peroxide versus normal saline” NCT02383992 ↗ “hydrogen peroxide topical solution 45%” NCT03687372 ↗ |
| Known as | A-101 | “An Open-Label Study Assessing Subject Satisfaction With A-101 Hydrogen Peroxide Topical Solution, 40% (w/w) Treatment for Seborrheic Keratoses of the Face, Neck, and Decolletage” NCT03487588 ↗11“Evaluate the safety and efficacy of hydrogen peroxide, A-101 Solution 40% for the treatment of DPN lesions on subjects with a Fitzpatrick Skin Type of 5 or 6.” NCT03224598 ↗ “A-101 45% (hydrogen peroxide 45% topical solution)” NCT03691831 ↗ |
| Known as | ActiveOxy | “1% Hydrogen peroxide (HP® by Karachi Chemicals Products Inc./ ActiveOxy® by Boumatic Inc.)” PMID 32928313 ↗ Sep 2020 |
| Known as | Crystacide | ChEMBL registry synonym — accepted as the source's own label CHEMBL71595 ↗ |
| Known as | Eskata | ChEMBL registry synonym — accepted as the source's own label CHEMBL71595 ↗ |
| Known as | H2O2 | “Hydrogen peroxide (H2O2): Helps remove debris physically and has some antimicrobial activity, though its efficacy against bacteria is less well established.” NCT07486245 ↗8“Vigorously rinse with 15 ml of the 1.5% hydrogen peroxide (H2O2) (Peroxyl; Colgate-Palmolive, Guildford, UK) for 30 s” NCT04721457 ↗ “rinsing with: Group 1-0.2% Chlorhexidine digluconate (CHX); Group 2-1.5% Hydrogen peroxide (H2O2);” PMID 37542087 ↗ Aug 2023 “Hydrogen peroxide (H2O2) is a commonly used disinfectant for skin debridement.” NCT06812065 ↗ “hydrogen peroxide (H2O2) and hyaluronic acid (HA) combination formulation” PMID 39012233 ↗ Jul 2024 “Hydrogen peroxide (H2O2 1.80% )and hyaluronic acid” NCT07031388 ↗ “Intrapleural Hydrogen Peroxide (H_2O_2)” NCT07713329 ↗ “Hydrogen Peroxide ( H2O2)” NCT06030492 ↗ |
| Known as | Hioxyl | ChEMBL registry synonym — accepted as the source's own label CHEMBL71595 ↗ |
| Known as | HP40 | “40% (w/w) hydrogen peroxide topical solution (HP40).” PMID 30365590 ↗ Oct 2018 |
| Known as | Hydrogen peroxide solution | ChEMBL registry synonym — accepted as the source's own label CHEMBL71595 ↗ |
| Known as | Hyrogen peroxide | ChEMBL registry synonym — accepted as the source's own label CHEMBL71595 ↗ |
| Known as | NSC-19892 | ChEMBL registry synonym — accepted as the source's own label CHEMBL71595 ↗ |
| Known as | Opalescence Boost PF 40% | “Participants will receive in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) for the maxillary anterior teeth” NCT03163069 ↗ |
| Known as | Oroxid | “3% hydrogen peroxide (Oroxid®) versus standard of care (0.2% chlorhexidine digluconate)” NCT06045429 ↗ |
| Known as | Oximen 3% | “Hydrogen peroxide 1% (Oximen® 3%) (Reig Jofré, S.A., Spain).” NCT04707742 ↗ |
| Known as | Oxydol | ChEMBL registry synonym — accepted as the source's own label CHEMBL71595 ↗ |
| Known as | Perio Gel | “administer 1.7% hydrogen peroxide gel (Perio Gel®, QNT Anderson, Bismarck, ND) deep into the periodontal pocket” NCT05669560 ↗ |
| Known as | Peroxyl | ChEMBL registry synonym — accepted as the source's own label CHEMBL71595 ↗ |
| Known as | Whiteness HP | “The handling of 35% hydrogen peroxide (Whiteness HP, FGM, Joinville, SC, Brazil) followed the manufacturer's recommendations, which consisted of mixing 3 drops of 35%hydrogen...” NCT03019224 ↗ |
| Known as | Whiteness HP Maxx | “A 35% hydrogen peroxide based bleaching agent (Whiteness HP Maxx, FGM, Joinville, SC, Brazil) will be mixed and applied on the vestibular surface of teeth, in the ratio of 1...” NCT02935114 ↗ |
| Modality | Small molecule | — CHEMBL71595 ↗ |
| Route | Topical | “when applied topically up to 2 times to SK target lesions on the face.” NCT02260180 ↗ |